Skip to main content
Erschienen in: International Urology and Nephrology 9/2017

31.05.2017 | Urology - Review

Renal cell cancers: unveiling the hereditary ones and saving lives—a tailored diagnostic approach

verfasst von: Georgios Kallinikas, Helai Habib, Dimitrios Tsimiliotis, Evangelos Koutsokostas, Barna Bokor

Erschienen in: International Urology and Nephrology | Ausgabe 9/2017

Einloggen, um Zugang zu erhalten

Abstract

The prevalence of RCC in Europe is 2–3% and increasing every year. Hereditary predisposition is found in 5–8% of all RCC cases. Hereditary syndromes associated with RCC include: Von Hippel–Lindau, hereditary papillary renal cell carcinoma, Birt–Hogg–Dube’, hereditary leiomyomatosis, succinate dehydrogenase’s deficiency, tuberous sclerosis complex and Cowden’s syndrome. These syndromes are related to specific genetic mutations. So far the European Association of Urology and American Urological Association have not established guidelines for referral of patients with RCC for germline mutation screening. The scope of this article is to review which clinical manifestations should direct clinicians’ thinking towards hereditary kidney carcinomas and therefore suggest which patients could benefit from genetic testing.
Literatur
2.
Zurück zum Zitat Joaquim AF, Ghizoni E, Tedeschi H, Pereira EB, Giacomini LA (2013) Stereotactic radiosurgery for spinal metastases: a literature review. Einstein São Paulo Braz 11(2):247–255CrossRef Joaquim AF, Ghizoni E, Tedeschi H, Pereira EB, Giacomini LA (2013) Stereotactic radiosurgery for spinal metastases: a literature review. Einstein São Paulo Braz 11(2):247–255CrossRef
3.
4.
Zurück zum Zitat Motzer RJ, Russo P, Nanus DM, Berg WJ (1997) Renal cell carcinoma. Curr Probl Cancer 21(4):185–232CrossRefPubMed Motzer RJ, Russo P, Nanus DM, Berg WJ (1997) Renal cell carcinoma. Curr Probl Cancer 21(4):185–232CrossRefPubMed
7.
Zurück zum Zitat Gudbjartsson T, Jónasdóttir TJ, Thoroddsen A et al (2002) A population-based familial aggregation analysis indicates genetic contribution in a majority of renal cell carcinomas. Int J Cancer 100(4):476–479CrossRefPubMed Gudbjartsson T, Jónasdóttir TJ, Thoroddsen A et al (2002) A population-based familial aggregation analysis indicates genetic contribution in a majority of renal cell carcinomas. Int J Cancer 100(4):476–479CrossRefPubMed
8.
Zurück zum Zitat Riley BD, Culver JO, Skrzynia C et al (2012) Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns 21(2):151–161CrossRefPubMed Riley BD, Culver JO, Skrzynia C et al (2012) Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns 21(2):151–161CrossRefPubMed
9.
Zurück zum Zitat Robson ME, Bradbury AR, Arun B et al (2015) American Society of Clinical Oncology Policy Statement Update: genetic and genomic testing for cancer susceptibility. J Clin Oncol Off J Am Soc Clin Oncol 33(31):3660–3667CrossRef Robson ME, Bradbury AR, Arun B et al (2015) American Society of Clinical Oncology Policy Statement Update: genetic and genomic testing for cancer susceptibility. J Clin Oncol Off J Am Soc Clin Oncol 33(31):3660–3667CrossRef
10.
Zurück zum Zitat Axwijk PH, Kluijt I, de Jong D, Gille H, Teertstra J, Horenblas S (2010) Hereditary causes of kidney tumours. Eur J Clin Invest 40(5):433–439CrossRefPubMed Axwijk PH, Kluijt I, de Jong D, Gille H, Teertstra J, Horenblas S (2010) Hereditary causes of kidney tumours. Eur J Clin Invest 40(5):433–439CrossRefPubMed
11.
Zurück zum Zitat Zbar B, Glenn G, Merino M et al (2007) Familial renal carcinoma: clinical evaluation, clinical subtypes and risk of renal carcinoma development. J Urol 177(2):461–465 (discussion 465) CrossRefPubMed Zbar B, Glenn G, Merino M et al (2007) Familial renal carcinoma: clinical evaluation, clinical subtypes and risk of renal carcinoma development. J Urol 177(2):461–465 (discussion 465) CrossRefPubMed
12.
13.
Zurück zum Zitat Lindor NM, McMaster ML, Lindor CJ, Greene MH, National Cancer Institute, Division of Cancer Prevention, Community Oncology and Prevention Trials Research Group (2008) Concise handbook of familial cancer susceptibility syndromes—second edition. J Natl Cancer Inst Monogr 38(1):1–93 Lindor NM, McMaster ML, Lindor CJ, Greene MH, National Cancer Institute, Division of Cancer Prevention, Community Oncology and Prevention Trials Research Group (2008) Concise handbook of familial cancer susceptibility syndromes—second edition. J Natl Cancer Inst Monogr 38(1):1–93
17.
Zurück zum Zitat Gad S, Lefèvre SH, Khoo SK et al (2007) Mutations in BHD and TP53 genes, but not in HNF1beta gene, in a large series of sporadic chromophobe renal cell carcinoma. Br J Cancer 96(2):336–340CrossRefPubMed Gad S, Lefèvre SH, Khoo SK et al (2007) Mutations in BHD and TP53 genes, but not in HNF1beta gene, in a large series of sporadic chromophobe renal cell carcinoma. Br J Cancer 96(2):336–340CrossRefPubMed
18.
Zurück zum Zitat Schmidt L, Junker K, Nakaigawa N et al (1999) Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 18(14):2343–2350CrossRefPubMed Schmidt L, Junker K, Nakaigawa N et al (1999) Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 18(14):2343–2350CrossRefPubMed
19.
Zurück zum Zitat Violette PD, Kamel-Reid S, Graham GE et al (2014) Knowledge of genetic testing for hereditary kidney cancer in Canada is lacking: the results of the Canadian national hereditary kidney cancer needs assessment survey. Can Urol Assoc J 8(11–12):E832–E840CrossRefPubMedPubMedCentral Violette PD, Kamel-Reid S, Graham GE et al (2014) Knowledge of genetic testing for hereditary kidney cancer in Canada is lacking: the results of the Canadian national hereditary kidney cancer needs assessment survey. Can Urol Assoc J 8(11–12):E832–E840CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Wallen EM, Pruthi RS, Joyce GF, Wise M, Urologic Diseases in America Project (2007) Kidney cancer. J Urol 177(6):2006–2019CrossRefPubMed Wallen EM, Pruthi RS, Joyce GF, Wise M, Urologic Diseases in America Project (2007) Kidney cancer. J Urol 177(6):2006–2019CrossRefPubMed
21.
Zurück zum Zitat Trepanier A, Ahrens M, McKinnon W et al (2004) Genetic cancer risk assessment and counseling: recommendations of the national society of genetic counselors. J Genet Couns 13(2):83–114CrossRefPubMed Trepanier A, Ahrens M, McKinnon W et al (2004) Genetic cancer risk assessment and counseling: recommendations of the national society of genetic counselors. J Genet Couns 13(2):83–114CrossRefPubMed
22.
Zurück zum Zitat Purdue MP, Johansson M, Zelenika D et al (2011) Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat Genet 43(1):60–65CrossRefPubMed Purdue MP, Johansson M, Zelenika D et al (2011) Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat Genet 43(1):60–65CrossRefPubMed
23.
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90CrossRefPubMed Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90CrossRefPubMed
24.
Zurück zum Zitat Shuch B, Vourganti S, Ricketts CJ et al (2014) Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. J Clin Oncol 32(5):431–437CrossRefPubMed Shuch B, Vourganti S, Ricketts CJ et al (2014) Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. J Clin Oncol 32(5):431–437CrossRefPubMed
25.
Zurück zum Zitat Schmidt LS, Nickerson ML, Angeloni D et al (2004) Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met proto-oncogene. J Urol 172(4 Pt 1):1256–1261CrossRefPubMed Schmidt LS, Nickerson ML, Angeloni D et al (2004) Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met proto-oncogene. J Urol 172(4 Pt 1):1256–1261CrossRefPubMed
27.
Zurück zum Zitat Grubb RL, Franks ME, Toro J et al (2007) Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol 177(6):2074–2080CrossRefPubMed Grubb RL, Franks ME, Toro J et al (2007) Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol 177(6):2074–2080CrossRefPubMed
28.
Zurück zum Zitat Pavlovich CP, Grubb RL, Hurley K et al (2005) Evaluation and management of renal tumors in the Birt–Hogg–Dubé syndrome. J Urol 173(5):1482–1486CrossRefPubMed Pavlovich CP, Grubb RL, Hurley K et al (2005) Evaluation and management of renal tumors in the Birt–Hogg–Dubé syndrome. J Urol 173(5):1482–1486CrossRefPubMed
29.
Zurück zum Zitat Walther MM, Choyke PL, Weiss G et al (1995) Parenchymal sparing surgery in patients with hereditary renal cell carcinoma. J Urol 153(3 Pt 2):913–916PubMed Walther MM, Choyke PL, Weiss G et al (1995) Parenchymal sparing surgery in patients with hereditary renal cell carcinoma. J Urol 153(3 Pt 2):913–916PubMed
30.
Zurück zum Zitat Lubensky IA, Schmidt L, Zhuang Z et al (1999) Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol 155(2):517–526CrossRefPubMedPubMedCentral Lubensky IA, Schmidt L, Zhuang Z et al (1999) Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol 155(2):517–526CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Schmidt LS, Warren MB, Nickerson ML et al (2001) Birt–Hogg–Dubé syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am J Hum Genet 69(4):876–882CrossRefPubMedPubMedCentral Schmidt LS, Warren MB, Nickerson ML et al (2001) Birt–Hogg–Dubé syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am J Hum Genet 69(4):876–882CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Duffey BG, Choyke PL, Glenn G et al (2004) The relationship between renal tumor size and metastases in patients with von Hippel–Lindau disease. J Urol 172(1):63–65CrossRefPubMed Duffey BG, Choyke PL, Glenn G et al (2004) The relationship between renal tumor size and metastases in patients with von Hippel–Lindau disease. J Urol 172(1):63–65CrossRefPubMed
33.
Zurück zum Zitat Wei M-H, Toure O, Glenn GM et al (2006) Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet 43(1):18–27CrossRefPubMed Wei M-H, Toure O, Glenn GM et al (2006) Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet 43(1):18–27CrossRefPubMed
34.
Zurück zum Zitat Reaume MN, Graham GE, Tomiak E et al (2013) Canadian guideline on genetic screening for hereditary renal cell cancers. Can Urol Assoc J 7(9–10):319–323CrossRefPubMedPubMedCentral Reaume MN, Graham GE, Tomiak E et al (2013) Canadian guideline on genetic screening for hereditary renal cell cancers. Can Urol Assoc J 7(9–10):319–323CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Miller FA, Krueger P, Christensen RJ, Ahern C, Carter RF, Kamel-Reid S (2009) Postal survey of physicians and laboratories: practices and perceptions of molecular oncology testing. BMC Health Serv Res 9:131CrossRefPubMedPubMedCentral Miller FA, Krueger P, Christensen RJ, Ahern C, Carter RF, Kamel-Reid S (2009) Postal survey of physicians and laboratories: practices and perceptions of molecular oncology testing. BMC Health Serv Res 9:131CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Silversides A (2007) The wide gap between genetic research and clinical needs. CMAJ Can Med Assoc J 176(3):315–316CrossRef Silversides A (2007) The wide gap between genetic research and clinical needs. CMAJ Can Med Assoc J 176(3):315–316CrossRef
37.
Zurück zum Zitat Weldon CB, Trosman JR, Gradishar WJ, Benson AB, Schink JC (2012) Barriers to the use of personalized medicine in breast cancer. J Oncol Pract Am Soc Clin Oncol 8(4):e24–e31CrossRef Weldon CB, Trosman JR, Gradishar WJ, Benson AB, Schink JC (2012) Barriers to the use of personalized medicine in breast cancer. J Oncol Pract Am Soc Clin Oncol 8(4):e24–e31CrossRef
38.
Zurück zum Zitat Crino PB, Nathanson KL, Henske EP (2006) The tuberous sclerosis complex. N Engl J Med 355(13):1345–1356CrossRefPubMed Crino PB, Nathanson KL, Henske EP (2006) The tuberous sclerosis complex. N Engl J Med 355(13):1345–1356CrossRefPubMed
39.
Zurück zum Zitat American Society of Clinical Oncology (2003) American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol Off J Am Soc Clin Oncol 21(12):2397–2406CrossRef American Society of Clinical Oncology (2003) American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol Off J Am Soc Clin Oncol 21(12):2397–2406CrossRef
Metadaten
Titel
Renal cell cancers: unveiling the hereditary ones and saving lives—a tailored diagnostic approach
verfasst von
Georgios Kallinikas
Helai Habib
Dimitrios Tsimiliotis
Evangelos Koutsokostas
Barna Bokor
Publikationsdatum
31.05.2017
Verlag
Springer Netherlands
Erschienen in
International Urology and Nephrology / Ausgabe 9/2017
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-017-1625-8

Weitere Artikel der Ausgabe 9/2017

International Urology and Nephrology 9/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.